Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Non-Current Assets (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Other Non-Current Assets for 13 consecutive years, with $738000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets changed N/A to $738000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $738000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $1.2 million for FY2025, 44.9% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $738000.0 at Aytu Biopharma, down from $939000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $2.5 million in Q2 2023, with the low at $457000.0 in Q4 2021.
  • Average Other Non-Current Assets over 5 years is $1.1 million, with a median of $859000.0 recorded in 2022.
  • The sharpest move saw Other Non-Current Assets skyrocketed 4596.97% in 2021, then crashed 52.36% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $457000.0 in 2021, then skyrocketed by 79.65% to $821000.0 in 2022, then rose by 10.48% to $907000.0 in 2023, then skyrocketed by 117.31% to $2.0 million in 2024, then plummeted by 62.56% to $738000.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $738000.0, $939000.0, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.